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Abstract: 
The phosphatidylinositol 3-kinase (PI3K) pathway is activated in ~70% of 
breast cancers. PIK3CA gene mutations or amplifications that affect the 
PI3K p110α subunit account for activation of this pathway in 20-40% of 
cases, particularly in estrogen-receptor alpha (ERα)-positive breast cancers. 
AKT family of kinases, AKT1-3, are the downstream targets of PI3K and 
these kinases activate ERα. Although several inhibitors of PI3K have been 
developed, none has proven effective in the clinic, partly due to an 
incomplete understanding of the selective routing of PI3K signaling to 
specific AKT isoforms. Accordingly, we investigated in this study the 
contribution of specific AKT isoforms in connecting PI3K activation to ERα 
signaling, and we also assessed the utility of using the components of PI3K-
AKT isoform-ERα signaling axis as predictive biomarkers of response to PI3K 
inhibitors. Using a variety of physiologically relevant model systems with 
defined natural or knock-in PIK3CA mutations and/or PI3K hyperactivation, 
we show that PIK3CA-E545K mutations (found in ~20% of PIK3CA-mutant 
breast cancers), but not PIK3CA-H1047R mutations (found in 55% of 
PIK3CA-mutant breast cancers), preferentially activate AKT1. Our findings 
argue that AKT1 signaling is needed to respond to estrogen and PI3K 
inhibitors in breast cancer cells with PIK3CA-E545K mutation, but not in 
breast cancer cells with other PIK3CA mutations. This study offers evidence 
that personalizing treatment of ER-positive breast cancers to PI3K inhibitor 
therapy may benefit from an analysis of PIK3CA-E545K-AKT1-estrogen 
signaling pathways. 
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Introduction: 
The phosphoinositide 3-kinase (PI3K) pathway is a commonly mutated/amplified 
pathway in cancers (1). Activating mutations of the p110, the catalytic subunit of PI3K, 
are common in Estrogen Receptor alpha (ER)-positive luminal breast cancers, whereas 
p110 is amplified frequently in ER-negative basal-like breast cancers (2). These 
observations suggest a crosstalk between signaling networks emanating from mutant 
PIK3CA and ER, which impacts breast cancer initiation and/or progression. 
ER is a nuclear receptor activated in response to its ligand estradiol (E2), and 
plays a significant role in >70% of breast cancers (3,4). In addition to E2, multiple co-
factors and posttranslational modifications control ER activity (4,5). These include 
pioneer factors such as FOXA1, GATA3, and AP2 that guide ER binding to the 
genome, transcriptional co-regulators that influence transcriptional output from ER, and 
ER phosphorylation that influences transcriptional activity, stability, and subcellular 
distribution (4). Several growth factor receptor activated kinases including AKT intersect 
with ER signaling by phosphorylating ER and altering transcriptional output (6).  
 AKT family of kinases (AKT1-3) are frequently activated downstream of PI3K. 
Published work from multiple groups including ours has shown significant influence of 
AKT in ER phosphorylation, genome-wide binding, E2-dependent mRNA and 
microRNA expression, and alternative splicing (7-11). We demonstrated distinct 
prognostic value of nuclear phospho-AKT in ER-positive breast cancers (12). However, 
there are two significant gaps in our understanding of crosstalk between PI3K and ER 
signaling, which this study is designed to address. First, the isoform of AKT that 
preferentially engages PI3K with ER is unknown. Second, it is unknown whether 
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PIK3CA-E545K mutation, which represents 20% of PIK3CA mutations, and PIK3CA-
H1047R mutation, which represents 55% of PIK3CA mutations in breast cancer 
(mycancergenome.org), has similar influence on AKT isoform activation. Exploring 
these gaps is critical because of recent understanding that AKT isoforms are not 
functionally similar (13,14). Moreover, commonly used constitutively active AKT 
mutants do not discriminate the functions of different isoforms of AKT (13). We focused 
on AKT1 and AKT2 because AKT3 is relevant for only ER-negative breast cancers 
(15,16). Our results showed that, in general, PIK3CA-E545K mutation is associated with 
AKT1 activation, whereas PI3KCA-H1047R mutation with activation of AKT1, AKT2, 
or both. AKT1 is essential for ER activity, E2-dependency, and response to PI3K 
inhibitors in MCF-7 cells with endogenous PIK3CA-E545K mutation. Thus, response of 
ER-positive breast cancers to PI3K inhibitors may depend on the isoform of AKT 
activated as a consequence of specific PIK3CA mutation. 
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Materials and Methods:  
 
Cell lines: MCF-7, T47-D, LY2, HCC1428, BT-474, SK-BR-3, MDA-MB-231, MDA-
MB-436, MDA-MB-468, UACC812, and ZR-75-1 cells were purchased from ATCC. 
600MPE cell line was a gift from Dr. Paul Spellman (17). HCC1428, UACC812 and LY2 
cell lines were purchased within last one year and other cell lines have been authenticated 
within past two years using STR Systems for Cell line identification (DNA Diagnosis 
Center, Fairfield, OH and Genetica DNA Laboratories, Cincinnati, OH). Human 
immortalized mammary epithelial cells (HMECs) with targeted replacement of PIK3CA 
with PIK3CA-E545K and PIK3CA-H1047R were purchased from Horizon Discovery 
Limited (hTERT-HME1, Cambridge, UK). Drs. Ben Ho Park and Michele Vitolo 
provided MCF10A cells with targeted PIK3CA mutants and PTEN deletion, respectively 
(18,19). Dr. Alex Toker provided the parental pLKO, AKT1, and AKT2 shRNA 
lentivirus vectors (20).  Supplementary information has additional details of lentivirus 
transfection, siRNAs, and cell proliferation assays. 
 
Antibodies: Antibodies against AKT1, AKT2, AKT1_pS473, AKT2_pS474, and 
phospho-GSK3/ (S9/21) were purchased from Cell Signaling Technology (Danvers, 
MA). Antibodies against ER, GATA3, GSK3/, FOXA1, cMyc, and Cyclin D1 were 
purchased from Santa Cruz Biotechnology, whereas AP2 antibody was from Epitomics 
(Burlingame, CA). 
 
RNA isolation, Microarray, and Quantitative Reverse Transcription Polymerase Chain 
Reaction (qRT-PCR): RNA was prepared using RNeasy kit (Qiagen, Valencia, CA) and 
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cDNA from two µgs of RNA was synthesized using the cDNA Synthesis kit (Bio-Rad, 
Hercules, CA). qRT-PCR was performed using SyberGreen on an Applied Biosystems 
7900HT instrument (Applied Biosystems, Carlsbad, CA). Sequences of primers used for 
qRT-PCR are in Supplementary Table S1. Microarray with biological triplicates was 
performed using Illumina HumanHT-12 V4 expression beadchip. Supplementary 
information contains additional details of microarray data analyses and results have been 
submitted to Gene Expression Omnibus (GSE60759). 
 
Transcription factor binding site (TFBS) enrichment analyses: The TFBS enrichment 
analysis was done using the MotifModeler tool (21). Briefly, MotifModeler uses array 
based gene expression data to identify functional binding sites by combining effects of 
binding sites of different transcription factors and estimating functional effects of 
predicted motifs under contrasting conditions. The tool makes assumption that 
differential gene expression is a feature of altered regulation and deduces differentially 
acting regulatory elements from a dataset of all regulatory elements based upon a list of 
differentially expressed genes. These binding sites are located within 1000 bases 5’ of the 
transcription start site and in the annotated 3’ untranslated region of genes. ER ChIP-
on-chip data and ChIP-seq data from our previous studies were used to assign ER 
binding sites (8,22).  
 
Analysis of signaling pathways overlap: FOXA1-E2 and PBX1-E2 signatures have been 
described previously (23). Gene lists for AKT1 and AKT2 dependent E2-induced genes 
were imported into Oncomine (24). Overlap was defined as significant at p value of at 
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least 0.01 and an Odds Ratio 2. Prognostic impact of FOXA1-E2-ER-AKT1 signature 
was evaluated using two public databases (25,26). 
 9 
Results: 
 
AKT isoform activity in breast cancer cell lines with endogenous PIK3CA 
aberrations. 
Recently developed antibodies that recognize activated AKT1 (AKT1_pS473) 
and AKT2 (AKT2_pS474) enabled us to reexamine whether specific isoforms are 
activated in response to distinct PI3K aberrations. Based on the studies using pan 
AKT_pS473 antibody, it was suggested that PIK3CA mutation is not always associated 
with AKT activation. For example, MCF-7 cells with PIK3CA-E545K mutation were 
reported to lack constitutive AKT activity (27). In contrast to the results reported using 
pan AKT_pS473 antibody, AKT1_pS473 was readily detected in MCF-7 cells under 
serum-deprived and serum-supplemented conditions (Figure 1A). AKT1_pS473 and 
AKT2_pS474 levels (to a lesser extent) in MCF-7 cells under serum-treated condition 
were higher than in 600MPE cell line, which lacks PIK3CA/PTEN alterations. 
AKT2_pS474 was dominant in T47-D cells with PIK3CA-H1047R mutation as its levels 
were higher compared with MCF-7 or 600MPE cell lines. Several additional cell lines 
(12 cell lines; LY2 is an anti-estrogen resistant derivative of MCF-7) were examined to 
determine whether PIK3CA mutation, PTEN mutation and/or HER2 amplification 
correlates with elevated basal and serum-inducible activated AKT1 or AKT2. All HER2-
amplified cell lines (BT-474, SK-BR-3, and UACC812) displayed elevated basal 
AKT1_pS473, AKT2_pS474, or both. For example, UACC812 cells with both HER2 
amplification and PIK3CA-N345K mutation displayed elevated AKT2_pS474, whereas 
SK-BR-3 with HER2 amplification showed elevated AKT1_pS473 compared with LY2 
cells (Figure 1A). BT-474 cells with HER2 amplification and PIK3CA-K111N mutation 
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displayed elevated levels of both AKT1_pS473 and AKT2_pS474 compared with 
600MPE or MCF-7 cells. Although additional well-characterized cell lines need to be 
examined, there was a trend of elevated AKT2_pS474 in cell lines with EGFR family 
amplification or overexpression (BT-474, UACC812, MD-468, and Hs578t). We also 
noted cell type-specific differences in serum-inducible AKT1 and AKT2 activity, as 
serum did not affect the levels of AKT1_pS473 and AKT2_pS474 in BT-474, ZR-75, 
LY2, UACC812, and MD-468 but increased their levels in MCF-7, T47-D, SK-BR-3, 
and Hs578t cells. Thus, multiple genomic events including PIK3CA mutation control 
AKT1 and AKT2 activity.  
 
AKT isoform activity in immortalized breast epithelial cell lines with PIK3CA-
E545K or PIK3CA-H1047R mutation. Since PIK3CA-E545K and PIK3CA-H1047R are 
the most common PIK3CA mutations in breast cancers, we further defined the link 
between specific PIK3CA mutation and AKT isoform activity using knock-in cell lines. 
HMECs and MCF10A cells with targeted replacement of one PIK3CA allele with either 
E545K or H1047R mutant allele were used (18). MCF10A cells with homozygous 
deletion of PTEN were used as a positive control (19). Under serum-starved condition (24 
hours), wild type HMECs displayed residual AKT1 activity, which was significantly 
higher in E545K and H1047R cells (Figure 1B). Under serum and growth factor 
supplemented condition, mutant cell lines displayed elevated AKT1 activity. Although 
PIK3CA mutation increased AKT2 activity, the effects were relatively modest. Thus, 
AKT1 is the major target of PIK3CA mutation in HMEC cells. Increased AKT1 activity 
 11 
in HMEC-E545K and HMEC-H1047R mutant cells correlated with elevated levels of its 
substrate phospho-GSK3/ (Figure 1C). 
Results were markedly different in MCF10A derivatives. Basal AKT1_pS473 and 
AKT2_pS474 levels were similar in serum-deprived parental and mutant MCF10A cells 
(Figure 1D). PTEN deletion and PIK3CA-H1047R mutation but not PIK3CA-E545K 
mutation resulted in elevated heregulin-induced AKT1_pS473 and AKT2_pS474 levels. 
These results indicated that PIK3CA mutations have cell type-specific effects on 
AKT1_pS473 and AKT2_pS474 levels under basal and/or growth factor stimulated 
condition. Interestingly, two out of three cell lines with PIK3CA-E545K mutation 
(HMEC-E545K and MCF-7 but not MCF10A-E545K) but no known growth factor 
receptor amplification, PTEN loss or K-Ras mutation showed preferential elevation of 
AKT1_pS473. By contrast, all PIK3CA-H1047R cell lines without growth factor receptor 
amplification, PTEN loss or K-Ras mutation (HMEC-H1047R, MCF10A-H1047R and 
T47-D) showed elevated levels of AKT1_pS473, AKT2_pS474, or both. Thus, it appears 
that, in the absence of other known confounding genomic events, PIK3CA-H1047R 
mutation is more potent in activating AKT than PIK3CA-E545K mutation. These results 
reveal distinct AKT isoform-driven signaling/biology downstream of PIK3CA-E545K 
and PIK3CA-H1047R mutation, which, to our knowledge, is not routinely considered 
while assessing the impact of PIK3CA aberration on cancer progression.  
Deciphering PIK3CA-E545K:AKT isoform:ER signaling axis in MCF-7 cells. 
One of our focuses was to determine how PIK3CA mutation and specific AKT 
isoform activation influence ER activity. MCF-7 cells are ideal for this purpose because 
these cells are ER-positive, E2-dependent, and contain PIK3CA-E545K mutation. A 
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recent study demonstrated that PIK3CA-E545K mutation is responsible for AKT activity 
in MCF-7 cells (28).  MCF10A, HMECs and their PIK3CA mutant derivatives are not 
ideal because these cells do not express ER and E2 treatment did not alter 
phosphorylation status of AKT1 or AKT2 in wild type or mutant MCF10A cells (data not 
shown). Since we observed an association between PIK3CA-E545K mutation and AKT1 
activation in MCF-7, our goal was to further evaluate whether AKT1 integrates signaling 
from PIK3CA-E545K mutation to ER through AKT1 or AKT2.  Towards this end, we 
generated cells expressing shRNA against AKT1 or AKT2 using previously validated 
shRNA constructs (20) (Figure 2A). Interestingly, AKT1 knockdown in these cells 
resulted in compensatory increase in AKT2.  
 We first examined pAKT_pS473 levels in MCF-7pLKO, AKT1KD, and 
AKT2KD cells upon activation of PI3K by heregulin. Heregulin-mediated AKT 
activation was lower in AKT1KD cells compared with control pLKO or AKT2KD cells 
(Figure 2B). There are two possible explanations for the observed effects of AKT1 
knockdown on heregulin-induced pAKT_pS473 levels; one is that heregulin 
preferentially activates AKT1 and the second is that AKT_pS473 antibody preferentially 
recognizes phosphorylated AKT1. To test these possibilities, we probed untreated and 
heregulin-treated MCF-7pLKO, AKT1KD and AKT2KD cells with AKT1_pS473 and 
AKT2_pS474 antibodies. As expected, heregulin-induced AKT1_pS473 levels were 
lower in AKT1KD cells (Figure 2C). Heregulin-induced AKT2 activation was unaffected 
in AKT1KD but reduced in AKT2KD cells. Therefore, lower levels of AKT_pS473 in 
heregulin-treated AKT1KD cells compared with pLKO or AKT2KD cells could be due to 
preferential recognition of phosphorylated AKT1 by this antibody. We consistently 
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observed lower AKT1_pS473 levels in AKT2 knockdown cells suggesting a regulatory 
role for AKT2 in controlling AKT1 activity. Similar results were obtained when cells 
were stimulated with insulin; AKT1_pS473 levels were lower in insulin-treated 
AKT1KD and AKT2KD cells compared with pLKO cells (Figure 2D).  
We performed two sets of experiments to link specific AKT isoforms to E2:ER 
signaling.  First, we examined whether AKT1 and AKT2 isoforms control the expression 
of ER and pioneer factors that regulate ER (29). AKT1 or AKT2 knockdown did not 
alter ER, GATA3, and FOXA1 levels. Basal expression of AP2 was lower in 
AKT1KD compared with pLKO or AKT2KD cells (Figure 3A). Among E2 inducible 
proteins tested, AKT1 or AKT2 knockdown had minimal effect on cMyc induction, 
whereas knockdown of either isoforms reduced E2-inducible Cyclin D1.  
Second, we performed microarray analysis of untreated and 3-hours E2-treated 
cells. AKT2 knockdown had greater effect than AKT1 knockdown on basal expression of 
genes (2982 genes versus 893 genes out of 15704 genes at p-value of <0.01 in the array 
with measurable expression, p=0.0001, Chi-square with Yates correction) (Table 1). In 
fact, AKT2 knockdown increased the basal expression of 2955 genes, which was 
significantly higher than the effect of AKT1 knockdown (656 genes, p=0.0001 AKT1 vs. 
AKT2). Thus, AKT2 potentially serves as a global suppressor of gene expression. 
Alternatively, distinct role of AKT1 and AKT2 in cell cycle may have indirectly 
contributed to differences in basal gene expression between three cell types (30). Names 
and fold-change in expression of genes along with ER binding pattern to these genes, 
determined based on previously described ChIP-seq or ChIP-on-Chip datasets, are 
presented in Table S2. TFBS enrichment analysis of genes differentially expressed under 
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basal condition revealed potential interaction between specific transcription factors and 
AKT isoform activated signals. For example, binding sites for TEF1, ATF6, AP2rep, 
SREBP1, ZF5, and CREB were observed in genes that are differentially expressed in 
AKT1KD or AKT2KD cells compared with pLKO cells (Figure 3B). By contrast, genes 
differentially expressed in AKT1KD cells were enriched for E2F, AP1, SP1, myogenin, 
AP2, AP2, STAT6, NERF1a, CP2, and NRF2 binding sites. Genes differentially 
expressed in AKT2KD cells were enriched for LEF1, AML, PEA3, SRY, MAZ, CRX, 
and USF2. Thus, AKT1 and AKT2 may target different transcription factors to modulate 
basal expression of genes.   
With p<0.01, we found 1912 genes to be E2-regulated in pLKO cells with 1682 
genes being induced. When the expression of these E2-regulated genes was analyzed 
after normalizing for basal expression in AKTKD cells, AKT1KD demonstrated higher 
effect than AKT2KD on E2-regulated gene expression (Table 1 and Table S3). For 
example, AKT1KD decreased E2-regulated expression of 405 genes but increased E2-
regulated expression of 33 genes. By contrast, AKT2 knockdown resulted in decreased 
E2-regulated expression of 201 genes but increased the expression of 15 genes. Only 104 
E2-regulated genes were commonly affected upon AKT1 or AKT2 knockdown. The 
differences in number of E2-regulated genes between AKT1KD and AKT2KD cells are 
statistically significant (p=0.0001, Fisher’s exact test, two-tailed). In summation, while 
AKT1 significantly influenced E2-regulated gene expression, AKT2 displayed a global 
role in controlling basal gene expression.  
We subjected E2-regulated genes differentially affected by AKT1 or AKT2 to 
Ingenuity Pathway analysis. E2-regulated genes requiring AKT1 are involved in 
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engaging ER to NF-B, p53-CDKN2A, and PI3 kinase-AKT-MAPK8-ERK pathways 
(Figure S1). By contrast, E2-regulated genes requiring AKT2 are involved in p53-
ERBB2-CCND1, FOS-Myc-C/EBP and RNA polymerase II-Histone H3-ERK1/2 
pathways (Figure S2). Pathway analysis revealing a link between AKT1 dependent E2-
regulated genes and PI3K pathway further suggests the involvement of AKT1 in 
integrating PI3K activation to ER signaling.  
AKT1-E2 and AKT2-E2-dependent genes are enriched for unique transcription 
factor binding sites.  
 To obtain insight into how AKT isoforms might differentially control the 
expression of E2 regulated genes, we assigned binding sites for ER, FOXA1, GATA3, 
p300, CBP, SRC1, SRC2, and SRC3 to each of the E2-regulated genes that were 
differentially affected by AKT isoforms (Table S3). Binding sites of these transcription 
co-regulators within 10-kB upstream of transcription start site and 5-kB downstream of 
the 3’ end of E2-regulated genes in MCF-7 cells have been described (31-33). Less than 
5% of genes differentially expressed in both cell types contained binding sites for p300, 
CBP, or any of the SRCs (Table S3). 50%, 60%, and 80% of differentially expressed 
genes contained ER, FOXA1, and GATA3 binding sites, respectively, with no AKT-
isoform-specific enrichment of binding sites.  
 Binding sites for the pioneer factors GATA3 and PBX1 were enriched in genes 
whose E2-dependent expression was affected in both AKT1KD and AKT2KD cells 
(Figure 3C). AP2, STAT5, and FOXO1 binding sites were enriched in genes that were 
dependent on AKT1 for E2-regulated expression (Figure 3C). By contrast, binding sites 
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for NF-B and NKX2-5 were enriched in genes that were dependent on AKT2 (Figure 
3C).  
 It is interesting that few of the transcription factors noted above have previously 
been shown to be E2-regulated and mediate secondary E2 response (34). AKT isoform 
dependency of several of the E2-regulated genes could be due to differential influence of 
AKT1 and AKT2 isoforms on E2-dependent expression of these transcription factors. 
Indeed, majority of these transcription factors including E2F family members are E2-
regulated in our cell lines and AKT1 and AKT2 knockdown had differential effect on 
their E2-regulated expression (Figure 3D). Collectively, these results suggest that AKT 
isoforms differentially regulate primary and secondary E2-response genes. 
Cyclin D1, in addition to being E2-inducible, interacts with ER and influences 
the expression of >2000 E2-regulated genes (35).  We analyzed the effect of AKT 
isoform knockdown on top 50 of Cyclin D1-ER-regulated genes. Out of 38 genes that 
overlapped between Cyclin D1-ER and AKT-isoform-ER datasets, E2-regulated 
expression of only two genes intersected with Cyclin D1-ER and AKT1-ER axis 
(MSMB and IL17RB, Table S3) and none with AKT2. Thus, AKT isoforms appears to 
have minimum role in regulating Cyclin D1-ER axis.  
Identification of PIK3CA-E545K:AKT1:ER:E2 gene expression signature. 
 Among the pioneer factors that control ER:E2-mediated gene expression, 
prognostic utility of E2:ER:FOXA1 and E2:ER:PBX1 regulated genes has been 
described (23).  FOXA1-E2 regulated genes are associated with good outcome whereas 
PBX1-E2 regulated genes are associated with poor outcome. We restricted our analysis to 
genes of these signatures and determined the influence of AKT1 and AKT2 on their 
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expression. Neither AKT1 nor AKT2 had an influence on PBX1-E2 gene expression 
signature. By contrast, FOXA1-E2 dependent genes were preferentially associated with 
AKT1 (p<7.9 10
-9
 and Odd ratio 17.7) (Table S4).  
To determine the influence of E2-regulated genes that are additionally controlled 
by AKT1 (called FOXA1-E2-AKT1 signature hereafter), we analyzed the impact of 
FOXA1-E2-AKT1 signature in the publicly available dataset, which allowed a combined 
analysis of tumors of 2977 patients (25). Data for CXCL12, PLAC1, SGK1, SLC22A5, 
and TGM2 were available in this database and all of them were positively regulated by 
AKT1. Elevated expression of genes in the signature was associated with better 
recurrence-free survival in luminal A and luminal B breast cancer (Figure 3E). This 
signature had similar effect on outcome in patients treated with endocrine therapy, 
tamoxifen therapy, or surgery alone (Figure 3E).  Also, the signature predicted better 
distant metastasis-free survival in patients with luminal A, luminal B breast cancers, and 
patients who did not receive systemic therapy (Figure 3E). Thus, FOXA1-E2-AKT1 
signature likely defines a cancer type with robust hormone receptor activity.  
We independently validated the above results using a resource developed by our 
group (26). In Wang et al dataset (36), elevated expression of this signature was 
associated with favorable recurrence-free survival among patients with ER-positive 
breast cancer (Figure S3). In the Loi et al dataset (37), elevated expression of this 
signature was associated with better outcome in tamoxifen-treated patients. In the TCGA 
dataset, elevated expression of this signature was associated with favorable overall 
survival of patients with PR-positive and a trend in ER-positive breast cancer.  
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We performed additional analysis to find a relationship between genes 
differentially influenced by AKT1 or AKT2 under basal or E2-treated condition and 
various other ER-positive breast cancer-specific prognostic signatures including SRC-1, 
SRC-2, SRC-3, p300, CBP (32), and tamoxifen resistance signatures (38). AKT1 or 
AKT2 knockdown had minimum effect on the expression of genes in these signatures. 
Thus, the signature identified above is unique to AKT1 and is not related to other 
signatures of ER-positive breast cancer. 
Recent studies have described an ER-dependent E2F-mediated resistance to 
aromatase inhibitors (39). Our array contained detectable expression of 17 out of the 24 
genes of this signature. Nine of these genes at p<0.01 were E2 inducible (Table S4). 
Seven of these genes lost E2 inducible expression in AKT1KD or AKT2KD cells.  Thus, 
AKT influences the expression of genes associated with anti-estrogen resistance, 
although the effects are not isoform-specific. 
Validation of E2-regulated genes that are differentially influenced by AKT1 and 
AKT2 in MCF-7 cells. 
 We performed qRT-PCR analysis of several of the genes in the FOXA1-E2-
AKT1 signature and other E2-regulated genes to verify the effects of AKT1 and AKT2 
knockdown. Consistent with the results of microarray, E2 failed to increase RERG and 
KCNK6 in AKT1KD cells compared with parental cells (Figure 4A). Although RERG 
expression was partially affected in AKT2KD cells, KCNK6 was E2-inducible in these 
cells. Similarly, E2-inducible expression of SIAH2 was significantly lower in AKT1KD 
cells compared with pLKO or AKT2KD cells. E2-inducible expression of SLC22A5 was 
lower in AKT1KD cells compared with AKT2KD cells. With respect to E2 repressed 
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genes, E2 readily repressed embryonic stem cell gene SALL4 in pLKO cells (40), which 
was inefficient in AKT1KD cells (Figure 4B). E2-mediated repression of BTG2, a breast 
cancer tumor suppressor (41), was enhanced in AKT1KD and AKT2KD cells (Figure 
4B). These results further confirm the ability of AKT1 and AKT2 to distinctly modulate 
E2-regulated gene expression. 
AKT1 influences response of MCF-7 cells to E2 and PI3K inhibitors.   
 We next examined the effect of AKT1 and AKT2 knockdown on E2-stimulated 
proliferation. Early passage AKT1KD cells demonstrated least E2-stimulated 
proliferation (Figure 5A). However, AKT knockdown cells remained as sensitive as 
pLKO cells to tamoxifen (Figure 5B). 
 We next tested whether AKT1 isoforms have specific role in determining 
sensitivity to PI3K-specific inhibitor BYL719, pan-PI3K inhibitor BKM120, 
PI3K/mTOR dual inhibitor NVP-BEZ235, and pan-AKT inhibitor MK2206. AKT1 
levels determined sensitivity to BYL719, as AKT1KD cells were resistant to this drug 
compared with pLKO or AKT2KD cells (for example, 20% survival of pLKO cells 
compared with 80% survival of AKT1KD cells when treated with 100 nM drug, Figure 
5B). Interestingly, E2 treatment significantly reduced sensitivity to this drug irrespective 
of AKT isoform knockdown suggesting the existence of E2:ER-dependent resistance 
mechanism to this class of inhibitors. AKT1KD cells demonstrated a modest increase in 
sensitivity to BKM120 under basal growth condition but the sensitivity was reversed 
upon E2 addition (Figure 5C). AKT1 and AKT2 knockdown had statistically significant 
effects on sensitivity to NVP-BEZ235 and MK2206 but the effects were numerically 
modest (Figure 5D and E). AKT2KD cells showed resistance to MK2206 under E2 
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treated condition (Figure 5E). These results indicate that AKT1 has significant influence 
on sensitivity to PI3K-specific inhibitors compared with AKT2. 
AKT isoforms are not essential for E2 response in BT-474 cells. 
 To determine whether AKT1:ER signaling axis extends beyond MCF-7 cells, 
we examined the role of AKT1 and AKT2 in E2 and PI3K inhibitor response in BT-474 
with PIK3CA-K111N mutation and HER2 amplification. In these cells, knockdown of 
both AKT1 and AKT2 reduced heregulin-induced AKT1_pS473 levels (Figure 6A). By 
contrast, unlike in MCF-7 cells, AKT1 knockdown reduced heregulin-induced 
AKT2_pS474 levels. Thus, type of crosstalk between AKT isoforms is cell type-specific.  
 Unlike in MCF-7 cells, where AKT1 and AKT2 knockdown did not reproducibly 
affect basal proliferation (data not shown), knockdown of both isoforms of AKT reduced 
basal proliferation but not E2-inducible proliferation of BT-474 cells (Figure 6B and C). 
Consistent with the limited role of AKT isoforms in E2-mediated proliferation, E2-
induced SIAH2 expression was unaffected by either AKT1 or AKT2 knockdown in these 
cells (Figure 6D). With respect to PIK3CA/mTOR inhibitor response, BT-474 cells were 
not sensitive to BYL719 (data not shown). However, these cells were sensitive to NVP-
BEZ235 (Figure 6E). Interestingly, AKT1KD and AKT2KD cells showed partial 
resistance to this drug, although statistical significance was achieved only in AKT2KD 
cells. Thus, AKT inhibition may force BT-474 cells to adapt to alternative survival 
mechanism independent of PI3K signaling.  
 
Discussion 
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Discovery of recurrent activating mutation of PIK3CA in a variety of cancers has 
prompted the development of PI3K inhibitors as cancer therapeutics (42,43). Response to 
these inhibitors has not always been correlated with PIK3CA mutations suggesting that 
additional pathways control therapeutic response. In this regard, Myc, eIF4E, RSK3/4 
and JAK/STAT pathways are suggested to be involved in conferring resistance to these 
inhibitors (1). Our results show significant cell type specificity in AKT isoform activation 
upon PIK3CA mutation and the unique ability of activated AKT1 downstream of 
PIK3CA-E545K mutation in determining E2 response and sensitivity to PI3K inhibitors. 
Recently developed antibodies against activated AKT1 and AKT2 allowed us to 
make major stride in defining the role of AKT isoforms in the context of PIK3CA 
mutation. We observed cell type-specific differences in basal levels of activated AKT1 
and AKT2 suggesting that genomic aberrations can lead to biased activation of these 
isoforms. These reagents allowed us to reexamine one of the earlier observations 
regarding basal AKT activity in breast cancer cell lines with PIK3CA mutation. For 
example, MCF-7 cells, despite containing PIK3CA-E545K mutation, were reported to 
lack activated AKT based on western blot analysis with AKT_pS473 antibody (27). 
However, we detected AKT1_pS473 in these cells.  
Cell type specific role of AKT isoforms in E2 signaling.  
AKT1 knockdown had much higher effect on E2-regulated gene expression and 
proliferation compared with AKT2 knockdown in MCF-7 cells. AKT1 activation in 
MCF-7 cells is dependent on PIK3CA-E545K mutation (28) and results presented in 
Figures 1 and 2 suggest preferential effect of this PIK3CA mutation on AKT1 activation. 
Therefore, PIK3CA mutation in this cell line could contribute to ER activity through 
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activation of AKT1.  In this regard, among ER-positive cell lines, MCF-7 has been the 
workhorse for ER-related studies because of its dependence on E2 for survival and 
studies using this cell line have provided clinically applicable biomarkers of anti-estrogen 
sensitivity. Unfortunately, there is no other ER-positive cell line with PIK3CA-E545K 
mutation to verify the results of MCF-7 cells.  
In BT-474 cells with distinct PIK3CA mutation and HER2 amplification, AKT 
isoforms were not required for E2 response (Figure 6). Alternative signaling pathway 
activation due to HER2 amplification may have rendered AKT isoforms redundant for 
ER signaling in these cells. HER2 can activate MAPKs, which can also increase ER 
activity (44).  Therefore, multiple genomic aberrations need to be taken into 
consideration before concluding whether mutant PIK3CA integrates with ER signaling 
through AKT isoforms.  
The mechanisms leading to preferential engagement of AKT1 over AKT2 in 
eliciting optimal E2 response in MCF-7 cells are unknown. Both AKT1 and AKT2 
phosphorylate ER; therefore, difference in ER phosphorylation is less likely to 
account for differential effects on E2 signaling (7,45). AKT1 and AKT2 share common 
upstream activators but frequently target distinct downstream molecules such as EMSY 
and Palladin (20,46). Therefore, a likely scenario includes specific engagement of AKT1 
with ER co-regulatory molecules, histone modifying enzymes, or pioneer factors. We 
observed lower expression of the pioneer factor AP2 in AKT1KD cells and AP2 
binding sites are enriched in genes that are dependent on AKT1 (Figure 3). A recent 
study demonstrated a role of AP2 in chromatin binding of unliganded ER and 
unliganded ER regulating AP2 expression (47).  AP2 is also essential for ER-
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mediated long-range chromatin interaction (48). It is likely that AKT1 serves as a central 
node in connecting AP2 to ER signaling. Since our results showed specific effects of 
AKT1 on E2-regulated gene expression and AKT2 on basal gene expression in MCF-7 
cells, we propose that, depending on the cell type, some of the genomic effects attributed 
to PI3K/AKT signaling are dependent on isoforms of AKT that are activated. Within this 
gene network, FOXA1:ER:E2:AKT1 activated signature is associated with better 
clinical outcome, similar to the recently described ER:E2:PLK1 signature (49).  These 
specific kinase dependent E2 gene expression signatures are likely predictive markers of 
E2-dependency and response to targeted therapies. In this context, AKT1 knockdown 
reduced the sensitivity to PI3K inhibitors in MCF-7 cells (Figure 5), suggesting that 
lower levels of AKT1 force cells to adapt to alternative survival pathways.  Alternatively, 
AKT1 may actively suppress the activation of compensatory survival pathways similar to 
the previously suggested role of AKT in suppressing Raf-dependent ERK activation (50). 
Clinically, tumors with active AKT1 and ER signaling may show higher sensitivity to 
PI3K inhibitors. However, developing markers of sensitivity to these drugs may prove 
difficult because of cell type specificity observed in the effects of PIK3CA mutation on 
signaling by AKT isoforms. Nonetheless, focused analyses of PIK3CA-E545K-AKT1-
ER signaling axis may be useful in select number of cases.
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Table 1: The effects of AKT1 and AKT2 knockdown on basal and E2-regulated gene 
expression. Note that basal expression differences between cell types were normalized to 
one before calculating the effects of AKT1 and AKT2 knockdown on E2-regulated gene 
expression.  
 
Basal gene expression 
 Up-regulated Down-regulated 
AKT1 shRNA vs. Control 656* 237 
AKT2 shRNA vs. control 2955* 27 
*p=0.001 
E2-regulation after normalization of basal expression. 
Number of E2-inducible genes in parental cells 1682 
Number of E2-repressed genes  230 
Number of E2-regulated genes whose expression is decreased upon AKT1 
knockdown 
405** 
Number of E2-regulated genes whose expression increased upon AKT1 
knockdown 
33 
Number of E2-regulated genes whose expression decreased upon AKT2 
knockdown 
201** 
Number of E2-regulated genes whose expression increased upon AKT2 
knockdown 
15 
**p=0.0001 
 
 
 30 
Figure Legends: 
Figure 1: Relationship between PIK3CA mutation and AKT isoform 
expression/activity. A) AKT1_pS473 and AKT2_pS474 levels in breast cancer cell lines 
with and without PIK3CA/PTEN mutation and HER2 amplification. Data from cells 
grown in regular media as well as serum starved for 24 hours are shown. B) AKT1 and 
AKT2 activation in HMECs with targeted replacement of one copy of wild type PIK3CA 
with indicated mutants. Active AKT1 and AKT2 were measured using phospho-specific 
antibodies. Results from three batches of lysates from serum-starved cells are shown. C) 
PI3K-dependent activation of AKT1 in HMECs correlates with activation GSK3, its 
downstream target. D) AKT1 and AKT2 activation in MCF10A cells with targeted 
replacement of one copy of wild type PIK3CA with indicated mutation or deletion of 
PTEN. PTEN-/- cells and PIK3CA mutant cells were obtained from different labs; 
therefore, wild type cells from corresponding labs were included as controls.  
Figure 2: AKT1 and AKT2 activity in AKT isoform knockdown MCF-7 cells. A) 
AKT1 and AKT2 levels in AKT1KD and AKT2KD MCF-7 cells. B) Effects of AKT1 
and AKT2 knockdown on heregulin-induced AKT phosphorylation. C) The effect of 
AKT1 and AKT2 knockdown on basal and heregulin inducible (15 minutes treatment) 
levels of AKT1_pS473 and AKT2_pS474. Longer exposure of the gel is shown to 
demonstrate the effects of knockdown on basal AKT1 and AKT2 activity levels (*). D) 
The effect of AKT1 and AKT2 knockdown on insulin-mediated (INS, 50 ng/ml for 15 
minutes) AKT1 and AKT2 activation. 
Figure 3: The effects of AKT1 and AKT2 knockdown on E2 signaling in MCF-7 
cells. A) Expression levels of ER, pioneer factors, and E2-inducible proteins in different 
cell types. B) TFBS enriched in genes expressed differentially in AKT1KD and 
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AKT2KD cells compared with pLKO cells under basal condition. C) TFBS enriched in 
genes expressed differentially in AKT1KD and AKT2KD cells compared with pLKO 
cells under E2-treated condition. D) The effects of E2, AKT1 and AKT2 knockdown on 
the expression of transcription factors potentially involved in the expression of E2-
regulated genes. Table S2 provides detailed fold changes and p-values. E) Prognostic 
value of E2:ER:FOXA1:AKT1 signature. Kaplan-Meier curves for recurrence-free 
(RFS) and metastasis-free survival (DMFS) of breast cancer subtypes are shown. Gene 
expression pattern was split at median to classify as high or low expressers. 
Figure 4: Validation of the effects of AKT1 and AKT2 knockdown on E2-regulated 
gene expression. A) AKT1 but not AKT2 knockdown significantly reduced E2-inducible 
expression of KCNK6, RERG, and SIAH2 in MCF-7 cells. Basal expression in all three-
cell types was normalized to one. Mean ± standard errors (SE) are shown. B) AKT1 and 
AKT2 had gene-specific effects on E2-mediated gene repression.  
Figure 5: AKT1 and AKT2 isoform knockdown had distinct effects on E2-induced 
proliferation and PI3K/mTOR/AKT inhibitor sensitivity of MCF-7 cells. A) The 
effects of AKT1 and AKT2 knockdown on E2 induced proliferation. Cells were treated 
with E2 (0.1 nM), 4-hydroxy tamoxifen (Tam, 100 nM) or both for six days and cell 
proliferation was measured using bromodeoxyuridine-incorporation ELISA. Mean ±SE 
are shown. B) AKT1 knockdown had significant effect on sensitivity to BYL719. Cells 
were grown without (left) or with E2 (right). C) AKT1KD cells were more sensitive to 
BKM120 under basal growth condition (left), but resistant to this drug under E2-treated 
condition. D) AKT1KD cells were resistant to NVP-BEZ235 under E2-treated condition. 
E) AKT2 knockdown reduced sensitivity to MK2206 under E2-treated condition. While 
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the mean ± SE for MK2206 and NVP-BEZ235 are from biological replicates, results for 
BKM120 and BYL719 are representative data from technical replicates due to 
experimental variability.  
Figure 6: AKT1 and AKT2 knockdown had minimum effect of E2 signaling in BT-
474 cells: A) AKT1, AKT1_pS473, AKT2, and AKT2_pS474 levels in cells treated with 
control luciferase (luci), AKT1 and AKT2 siRNAs for four days. AKT isoform levels 
were measured in untreated and heregulin (15 minutes) treated cells. AKT1 and AKT2 
activities are mutually dependent in BT-474 cells. B) The effect of AKT1 and AKT2 
knockdown on basal proliferation of BT-474 cells. C) The effect of AKT1 and AKT2 
knockdown on E2-mediated cell proliferation and response to tamoxifen. Assays were 
performed as in Figure 5A except that tamoxifen concentration was one micromolar. Due 
to experimental variability, results of two experiments are shown separately (six 
replicates in each condition). D) The effect of AKT1 and AKT2 isoform knockdown on 
E2-regulated expression of SIAH2 and SALL4 as measured by qRT-PCR. E) AKT2 
knockdown cells were partially resistant to NVP-BEZ235 compared with control cells. 
AKT1 knockdown cells showed similar trend (p=0.06).  
 






